A case report of nifedipine-induced hepatitis with jaundice
| Autor: | Martin Fishman, Meghan Ho, David A. Owen, David K.B. Li, Dimas Yusuf, Joanna Christy |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Nifedipine Drug-induced liver injury Jaundice Drug-induced hepatitis lcsh:Medicine Case Report Side effect Gastroenterology General Biochemistry Genetics and Molecular Biology Hepatitis Angina 03 medical and health sciences 0302 clinical medicine Internal medicine Medicine Eosinophilia Humans 030212 general & internal medicine lcsh:Science (General) lcsh:QH301-705.5 Aged medicine.diagnostic_test business.industry lcsh:R Hepatocellular General Medicine Liver biopsy medicine.disease Calcium Channel Blockers Calcium channel blocker lcsh:Biology (General) Adverse events 030211 gastroenterology & hepatology Chills Female DILI Steatohepatitis medicine.symptom Chemical and Drug Induced Liver Injury business medicine.drug lcsh:Q1-390 |
| Zdroj: | BMC Research Notes, Vol 11, Iss 1, Pp 1-9 (2018) BMC Research Notes |
| ISSN: | 1756-0500 |
| DOI: | 10.1186/s13104-018-3322-9 |
| Popis: | Background: Nifedipine is a generic, well-known and commonly-prescribed dihydropyridine calcium channel blocker used in the treatment of hypertension and Prinzmetal’s angina. A known but very rare and serious adverse effect of nifedipine is clinically-apparent hepatitis which can take months to resolve. Case presentation: Here we present a case of nifedipine-induced hepatitis in a 78-year-old Caucasian female with no prior history of liver or autoimmune disease. We discuss our investigative and management approach, and present a review of prior cases. We offer an approach for patients who present with signs of acute liver injury with jaundice and high elevations in serum transaminases. Conclusion: Not much is known about nifedipine-induced hepatitis due to its rare occurrence. Its prevalence is unknown. The disease appears to afflict older men and women. It can present acutely (within days) or subacutely (within 4–8 weeks after medication start) and in an idiosyncratic manner. Chronic or latent cases have also been described, some diagnosed as late as 3 years after medication start. Common symptoms include jaundice, nausea, chills, rigors, diaphoresis, fatigue, and abdominal pain. Laboratory investigations often reveal profound elevations in AST, ALT, GGT, and conjugated bilirubin. Peripheral blood smear may demonstrate eosinophilia. Histology from liver biopsy typically demonstrates infiltration of immune cells, cholestasis, and a picture of steatohepatitis. Treatment involves immediate discontinuation of the drug with supportive care. Thus far, all published instances of nifedipine-induced hepatitis were self-limiting without mortality due to fulminant liver failure. However, this disease can take months to resolve. There is no randomized evidence for other treatments such as corticosteroids. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |